Owners of cats with the commonly fatal disease feline infectious peritonitis (FIP) have long awaited a reliable source for the drug GS-441524 to treat FIP, and a recent announcement by Stokes Pharmacy is great news on this front. GS-441524, the active metabolite of the antiviral medication remdesivir, has been shown to be safe and effective in treating FIP in clinical trials, and it has been used in Australia and the UK for some time.
Until this breaking news, though, cat owners and veterinarians in the United States were put in a bit of an uncomfortable situation in considering its use to treat FIP-infected cats, because, although its safety and effectiveness has been known for several years, it was not previously approved by the FDA.
This problem has prompted some owners to obtain GS-441524 on the black market out of understandable desperation. Unfortunately, recent evaluations of these black-market products show a great deal of variation in the amount of active drug present in these preparations.
This is why the recent announcement that Stokes Pharmacy released an oral compounded GS-441524 formulation on June 1, 2024, is such a ground-breaking announcement.
U.S. cat owners and veterinary professionals now have a reliable source of oral GS-441524, produced in the strict quality-controlled facilities of the Bova Group. A veterinary prescription will be required to obtain GS-441524 therapy for an FIP-infected cat, and we recommend that you consult with your veterinarian if you have any questions about how to obtain this game-changing novel therapy.
You can find out more about this exciting news at: https://www.stokespharmacy.com/stokes-bova-partner-for-feline-infectious-peritonitis-treatment/, and we will be sure to update the cat loving public about any new developments on this front as soon as we become aware of them.
